{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-004479","form_type":"8-K","ticker":"CRVS","cik":"0001626971","company_name":"Corvus Pharmaceuticals, Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.860373+00:00","generated_at":"2026-05-31T12:18:23.062410+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Corvus reports Q2 loss; soquelitinib shows early activity in atopic derm, PTCL Phase 3 on track","bullets":["Early soquelitinib Phase 1 atopic dermatitis data (3 evaluable patients, 100 mg BID) show clinical activity and cytokine changes consistent with ITK inhibition.","Phase 3 registrational trial for soquelitinib in PTCL to start Q3 2024; updated Phase 1/1b data: 39% ORR (6 CRs, 3 PRs) in 23 evaluable patients.","Cash, cash equivalents and marketable securities $47.2M as of June 30, 2024; Q2 2024 net loss $4.3M vs $6.5M prior year; cash runway into Q4 2025.","Ciforadenant Phase 1b/2 trial in RCC met interim efficacy threshold; enrollment continues. New U.S. patent issued for ciforadenant.","Soquelitinib received Fast Track designation for relapsed/refractory PTCL; FDA pediatric waiver granted for T cell lymphoma indication."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-004479","json":"https://secwatch.observer/filing/0001171843-24-004479.json","markdown":"https://secwatch.observer/filing/0001171843-24-004479.md","text":"https://secwatch.observer/filing/0001171843-24-004479.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626971/000117184324004479/0001171843-24-004479-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626971/000117184324004479/f8k_080624.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:18:23.062410+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}